Zycubo

(copper histidinate)

PreclinicalSmall molecule

SSentynl Therapeutics, Inc.

Zycubo is one of 9 small molecule programs targeting Menkes disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Menkes DiseaseActive, not recruiting

Menkes DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Menkes Disease

#DrugCompanyPhaseTrials

Fludara

Jakafi

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Busulfex

Dacogen

Alkeran

Northera

2 8

Copper Histidine

CCyprium Therapeutics, Inc.

Phase 2

2 9

Zycubo

SSentynl Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Menkes disease1 trial

Copper Histidinate Treatment for Menkes Disease

Approved for marketing·SSentynl Therapeutics, Inc.··NCT04074512

Regulatory

FDA Approval Timeline[4]

Jan 12, 2026

ZYCUBO

NDA NDA211241

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for copper histidinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — copper histidinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for copper histidinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA211241). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Sentynl Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSentynl Therapeutics, Inc.

Zycubo

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Menkes disease1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News